Goodman Advisory Group’s Bristol-Myers Squibb BMY Stock Holding History

Goodman Advisory Group’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-143	Closed	-$8.67K	–	81
2026 Q1	$8.67K	Sell	143 -504	-78%	-$29.4K	﹤0.01%	147
2025 Q4	$34.9K	Hold	647	–	–	0.01%	112
2025 Q3	$29.2K	Hold	647	–	–	0.01%	121
2025 Q2	$29.9K	Hold	647	–	–	0.01%	97
2025 Q1	$39.5K	Buy	+647	New	+$37.7K	0.01%	112
2024 Q4	–	Sell	-647	Closed	-$33.5K	–	68
2024 Q3	$33.5K	Hold	647	–	–	0.01%	127
2024 Q2	$26.9K	Hold	647	–	–	0.01%	129
2024 Q1	$35.1K	Hold	647	–	–	0.01%	107
2023 Q4	$33.2K	Hold	647	–	–	0.01%	99
2023 Q3	$37.6K	Hold	647	–	–	0.01%	98
2023 Q2	$41.4K	Sell	647 -4	-0.6%	-$268	0.02%	89
2023 Q1	$45.1K	Hold	651	–	–	0.02%	78
2022 Q4	$47K	Hold	651	–	–	0.03%	76
2022 Q3	$46K	Hold	651	–	–	0.03%	75
2022 Q2	$50K	Buy	+651	New	+$49.6K	0.02%	76

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Goodman Advisory Group's BMY Position: Q2 2026 in Review

Goodman Advisory Group sold out of Bristol-Myers Squibb (BMY) in Q2 2026, closing a stake of 143 shares — an estimated $8.67K sold.

Goodman Advisory Group first reported a position in BMY in Q2 2022 and held it in 15 quarters. The position peaked at $50K in Q2 2022. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Goodman Advisory Group reported no remaining Bristol-Myers Squibb position as of Q2 2026 after selling out during the quarter.
Goodman Advisory Group sold 143 Bristol-Myers Squibb shares in Q2 2026, an estimated $8.67K.
Goodman Advisory Group first reported a position in Bristol-Myers Squibb in Q2 2022 and held it in 15 quarters.
Goodman Advisory Group's Bristol-Myers Squibb position peaked at $50K in Q2 2022.
2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Goodman Advisory Group's 13F filing for Q2 2026, filed 12 Aug 2026.